The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Temozolomide for immunomodulation in the treatment of glioblastoma
Open accessAbstract
Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy. Due to the limited efficacy of existing therapies, immunotherapy is being widely investigated for patients with GBM. However, initial immunotherapy trials in GBM patients have had disappointing results as monotherapy. Therefore, combinatorial treatment strategies are being investigated. Temozolomide has several effects on the immune system that are dependent on mode of delivery and the dosing strategy, which may have unpredicted effects on immunotherapy. Here we summarize the immune modulating role of temozolomide alone and in combination with immunotherapies such as dendritic cell vaccines, T-cell therapy, and immune checkpoint inhibitors for patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“IL-7 and IL-15 are cytokines that increase proliferation of CD8 T cells and augment effector function, and these cytokines usually do not increase with temozolomide.”
BackgroundStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“Additionally, bevacizumab, which inhibits vascular endothelial growth factor, did not show benefit when added to radiotherapy-temozolomide for patients with newly diagnosed GBM. 2,3 In addition to combination therapy, variations in dosing temozolomide have been tested with mixed results.”
BackgroundBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
Shevach, E. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.010 · Cited by 1,754
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30517-x · Cited by 1,134
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K., Chongsathidkiet, P., Rhodin, K., Kemeny, H., Dechant, C., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 654
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., & Strober, W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.834 · Cited by 630
Fecci, P. E., Mitchell, D. A., Whitesides, J. F., Xie, W., Friedman, A. H., Archer, G. E., Herndon, J. E., Bigner, D. D., Dranoff, G., & Sampson, J. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3773 · Cited by 617
Self-citationImmunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Grossman, S. A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., & Piantadosi, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0774 · Cited by 578
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 531
Self-citationCancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Self-citationRaychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor042 · Cited by 359
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.-M., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.012 · Cited by 349
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 347
Self-citationAndaloussi, A. E., & Lesniak, M. S. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-006 · Cited by 311
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Batich, K. A., Reap, E. A., Archer, G. E., Sanchez-Perez, L., Nair, S. K., Schmittling, R. J., Norberg, P., Xie, W., Herndon, J. E., Healy, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2057 · Cited by 295
Self-citationRapoport, A. P., Stadtmauer, E. A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., et al. (2005) · Nature Medicine · doi:10.1038/nm1310 · Cited by 290
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination
Wheeler, C. J., Das, A., Liu, G., Yu, J. S., & Black, K. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0497 · Cited by 266
Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C., Williams, L., Foster, T., Sepkowitz, K. A., & Chapman, P. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.060 · Cited by 257
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196
Self-citationSystemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Bauer, M., Goldstein, M., Christmann, M., Becker, H., Heylmann, D., & Kaina, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111919109 · Cited by 187
Ma, D. J., Galanis, E., Anderson, S. K., Schiff, D., Kaufmann, T. J., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou328 · Cited by 171
Dubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., Wiendl, H., & Grauer, O. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov280 · Cited by 169
Gielen, P. R., Schulte, B. M., Kers-Rebel, E. D., Verrijp, K., Bossman, S. A. J. F. H., ter Laan, M., Wesseling, P., & Adema, G. J. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now034 · Cited by 164
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 156
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
Fadul, C. E., Fisher, J. L., Gui, J., Hampton, T. H., Côté, A. L., & Ernstoff, M. S. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq204 · Cited by 146
Desbaillets, I., Tada, M., de Tribolet, N., Diserens, A., Hamou, M., & Meir, E. G. V. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580216 · Cited by 143
Mitchell, D. A., Cui, X., Schmittling, R. J., Sanchez-Perez, L. A., Snyder, D. J., Congdon, K. L., Archer, G. E., Desjardins, A., Friedman, A. H., Friedman, H. S., et al. (2011) · Blood · doi:10.1182/blood-2011-02-334565 · Cited by 114
Self-citationSampson, J. H., Schmittling, R. J., Archer, G. E., Congdon, K. L., Nair, S. K., Reap, E. A., Desjardins, A., Friedman, A. H., Friedman, H. S., Herndon, J. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031046 · Cited by 109
Self-citationKong, D., Lee, J.-I., Kim, J. H., Kim, S. T., Kim, W. S., Suh, Y., Dong, S. M., & Nam, D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop030 · Cited by 100
Ellsworth, S. G., Balmanoukian, A. S., Kos, F. J., Nirschl, C. J., Nirschl, T. R., Grossman, S. A., Luznik, L., & Drake, C. G. (2014) · OncoImmunology · doi:10.4161/onci.27357 · Cited by 89
Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M.-Y., Pieper, R. O., Costello, J., VandenBerg, S. R., Parvataneni, R., Nicole, A., Sneed, P. K., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor130 · Cited by 77
Kim, T., Kim, C.-H., Park, J., Park, S.-D., Kim, C. K., Chung, D., & Hong, Y.-K. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00292-09 · Cited by 75
Learn, C. A., Fecci, P. E., Schmittling, R. J., Xie, W., Karikari, I. O., Mitchell, D. A., Archer, G. E., Wei, Z., Dressman, H. K., & Sampson, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1727 · Cited by 71
Self-citationProfound Impairment of Adaptive Immune Responses by Alkylating Chemotherapy
Litterman, A. J., Zellmer, D. M., Grinnen, K. L., Hunt, M. A., Dudek, A. Z., Salazar, A. Μ., & Ohlfest, J. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203539 · Cited by 71
Akasaki, Y., Kikuchi, T., Homma, S., Koido, S., Ohkusa, T., Tasaki, T., Hayashi, K., Komita, H., Watanabe, N., Suzuki, Y., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1905-7 · Cited by 67
Sanchez-Perez, L. A., Choi, B. D., Archer, G. E., Cui, X., Flores, C., Johnson, L. A., Schmittling, R. J., Snyder, D. J., Herndon, J. E., Bigner, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059082 · Cited by 66
Self-citationCampian, J. L., Piotrowski, A., Ye, X., Hakim, F. T., Rose, J. J., Yan, X.-Y., Lu, Y., Gress, R. E., & Grossman, S. A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2580-z · Cited by 66
Heimberger, A. B., Archer, G. E., McLendon, R. E., Hulette, C., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2000) · PubMed · Cited by 60
Darlix, A., Baumann, C., Lorgis, V., Ghiringhelli, F., Blonski, M., Chauffert, B., Zouaoui, S., Pinelli, C., Rech, F., Beauchesne, P. D., et al. (2013) · PubMed · Cited by 60
Ouyang, M., White, E. E., Ren, H., Guo, Q., Zhang, I., Gao, H., Song, Y., Chen, X., Weng, Y., Fonseca, A. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148139 · Cited by 53
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Thomas, A. A., Fisher, J. L., Rahme, G. J., Hampton, T. H., Baron, U., Olek, S., Schwachula, T., Rhodes, C. H., Gui, J., Tafe, L. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou363 · Cited by 52
Briegert, M., & Kaina, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3712 · Cited by 49
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
Fritzell, S., Sandén, E., Eberstål, S., Visse, E., Darabi, A., & Siesjö, P. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1449-z · Cited by 47
Lin, A. J., Campian, J. L., Hui, C., Rudra, S. F., Rao, Y. J., Thotala, D. K., Hallahan, D. E., & Huang, J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2668-5 · Cited by 41
Koumarianou, A. A., Christodoulou, M., Patapis, P., Papadopoulos, I. N., Liakata, E., Giagini, A. T., Stavropoulou, A., Poulakaki, F., Tountas, N. A., Xiros, N., et al. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-3 · Cited by 33
Faivre, C., Barbolosi, D., Pasquier, E., & André, N. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2095-z · Cited by 32
Glioblastoma-associated circulating monocytes and the release of epidermal growth factor
Fries, G., Perneczky, A., & Kempski, O. S. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0642 · Cited by 28
Wang, H., Cai, S., Ernstberger, A. G., Bailey, B. J., Wang, M. Z., Cai, W., Goebel, W. S., Czader, M., Crean, C., Suvannasankha, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2671 · Cited by 26
Litterman, A. J., Dudek, A. Z., & Largaespada, D. A. (2013) · OncoImmunology · doi:10.4161/onci.26294 · Cited by 22
Change in expression of MGMT during maturation of human monocytes into dendritic cells
Briegert, M., Enk, A., & Kaina, B. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.02.008 · Cited by 22
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
Wong, E. T., Timmons, J. J., Callahan, A., O’Loughlin, L., Giarusso, B., & Alsop, D. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2945-2 · Cited by 19
Cited by
Molecular mechanisms of ferroptosis and their involvement in brain diseases
Costa, I., Barbosa, D. J., Benfeito, S., Silva, V., Chavarria, D., Borges, F., Remião, F., & Silva, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108373 · Cited by 402
Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Van Ginderachter, J. A. (2020) · eLife · doi:10.7554/elife.52176 · Cited by 272
Liu, X., Cao, Z., Wang, W., Zou, C., Wang, Y., Pan, L., Jia, B., Zhang, K., Zhang, W., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12857 · Cited by 132
Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma
Shaikh, M. A. J., Altamimi, A. S. A., Afzal, M., Gupta, G., Singla, N., Gilhotra, R., almalki, W. H., Kazmi, I., Alzarea, S. I., Prasher, P., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155121 · Cited by 37
Immunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
Metadata
- Authors
- Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-04
- Volume
- 20
- Issue
- 12
- Pages
- 1566-1572
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2802299363
- Cited by
- 300
- References
- 73
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.